This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement

This study has been completed.
Ethicon Endo-Surgery
GE Healthcare
Information provided by:
Fred Hutchinson Cancer Research Center Identifier:
First received: October 22, 2007
Last updated: December 29, 2008
Last verified: December 2008
The purpose of this study is to determine how long collagen based marker clips remain visible by ultrasound after placement in suspicious breast lesions and if collagen based marker clips can be reliably identified in the operating room and serve as effective guidance for surgical removal of high risk or malignant breast lesions.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement

Resource links provided by NLM:

Further study details as provided by Fred Hutchinson Cancer Research Center:

Primary Outcome Measures:
  • Visibility of marker clip after placement in suspicious breast lesions. [ Time Frame: Within 4 weeks of placement ]

Biospecimen Retention:   None Retained
none/not applicable

Estimated Enrollment: 25
Study Start Date: May 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Many breast cancers and other breast lesions are discovered as a palpable abnormality by patients or their providers during a breast exam. Diagnostic imaging and biopsy of these lesions may reveal high-risk or malignant findings. These palpable lesions can be removed in the operating room by the surgeon using touch as guidance. However, there are many lesions discovered by screening examinations that surgeons cannot palpate. When this occurs, a radiologist will percutaneously place a wire or wires at the site of the breast lesion using sonographic or mammographic guidance. The surgeon then uses the wires as a guide for complete and successful resection of the lesion.

New marker devices have been developed that are sonographically visible. They consist of the standard mammographically visible metallic clip surrounded by a sonographically visible collagen plug. It is hypothesized that radiologists and surgeons can effectively localize the clip with intra-operative ultrasound and then resect the lesion. If so, the pre-operative wire localization procedure could be eliminated. This could improve the patient experience while saving time and money by reducing the number of invasive procedures from 3 (biopsy, wire-localization and operation) to 2 (biopsy and operation).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
outpatient clinic

Inclusion Criteria:

  • Patients with suspicious breast lesions that have undergone biopsy and marker clip placement within 28 days (4 weeks) of pre-operative consultation visit.
  • Patients or their legal representative must be able to provide written informed consent.
  • Patients must be over 18 years old.

Exclusion Criteria:

  • Under the age of 18 years
  • Unable to give written informed consent
  • Patients will be excluded if the clip was placed more than 4 weeks prior to their pre-operative appointment or wire-localization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00548392

United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109-1023
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
Ethicon Endo-Surgery
GE Healthcare
Principal Investigator: Peter R Eby, MD University of Washington
  More Information

Responsible Party: Peter Eby, University of Washington/SCCA Identifier: NCT00548392     History of Changes
Other Study ID Numbers: 6263
Study First Received: October 22, 2007
Last Updated: December 29, 2008

Keywords provided by Fred Hutchinson Cancer Research Center:
high risk
marker clip processed this record on September 21, 2017